ArticleJournal of thrombosis and thrombolysis2025
Decreased circulating microRNA-22 expression as a potential biomarker for predicting a higher risk of recurrent ischemic stroke related to inner carotid artery stenosis: a multicenter study.
Article in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNA Profiling of the Pathophysiological Mechanisms Underlying Carotid Atherosclerosis Progression.Biomolecules · 2026Review
- miR-493-3p alleviates carotid artery stenosis by targeting YTHDF2.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carotid endarterectomy has proved to be beneficial in the prevention of stroke in patients with carotid artery stenosis ≥ 70%, while the benefit in symptomatic patients with moderate stenosis (50-69%) was undetermined, and some of them may be at higher risk of recurrent ipsilateral stroke (RIS). To date, it's hard to define vulnerable populations and novel biomarkers should be exploited. Thus, we aim to explore the predictive role of miR-22 in the presence of RIS and the prognosis of symptomatic patients with moderate stenosis. 400 patients were prospectively recruited, and miR-22 levels were assessed. The incidence of RIS and major adverse cardiovascular and cerebrovascular events (MACCE)-free survival were presented and the risk factors for RIS and MACCE-free survival were investigated. The area under the curve (AUC) was also investigated for RIS. The degree of carotid artery stenosis was negatively associated with miR-22 level (P < 0.001). The median value of miR-22 was 4.16 in the overall distribution, patients with miR-22 levels ≥ 4.16 had a significantly improved MACCE-free survival (P = 0.012) and lower incidence of RIS (P = 0.020) compared with miR-22 levels < 4.16. The multivariable cox regression analysis demonstrated that patients with lower miR-22 levels were prone to the presence of RIS (P < 0.001). The AUC of miR-22 in predicting RIS was 0.662 (95% CI, 0.550-0.774). This study implies that lower miR-22 levels may play a predictive role in the higher incidence of RIS in patients with moderate stenosis. Moreover, lower miR-22 levels can also prognosticate a higher risk for MACCE in these patients.
Indexed as
Identifiers
40415140What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.